1. Home
  2. CALC vs ORIS Comparison

CALC vs ORIS Comparison

Compare CALC & ORIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CALC
  • ORIS
  • Stock Information
  • Founded
  • CALC 2011
  • ORIS 2014
  • Country
  • CALC United States
  • ORIS China
  • Employees
  • CALC N/A
  • ORIS N/A
  • Industry
  • CALC Biotechnology: Pharmaceutical Preparations
  • ORIS Farming/Seeds/Milling
  • Sector
  • CALC Health Care
  • ORIS Consumer Staples
  • Exchange
  • CALC Nasdaq
  • ORIS Nasdaq
  • Market Cap
  • CALC 22.9M
  • ORIS 12.1M
  • IPO Year
  • CALC N/A
  • ORIS 2024
  • Fundamental
  • Price
  • CALC $2.13
  • ORIS $0.65
  • Analyst Decision
  • CALC Strong Buy
  • ORIS
  • Analyst Count
  • CALC 2
  • ORIS 0
  • Target Price
  • CALC $14.50
  • ORIS N/A
  • AVG Volume (30 Days)
  • CALC 38.7K
  • ORIS 190.5K
  • Earning Date
  • CALC 08-11-2025
  • ORIS 02-21-2025
  • Dividend Yield
  • CALC N/A
  • ORIS N/A
  • EPS Growth
  • CALC N/A
  • ORIS N/A
  • EPS
  • CALC N/A
  • ORIS 0.17
  • Revenue
  • CALC N/A
  • ORIS $15,014,000.00
  • Revenue This Year
  • CALC N/A
  • ORIS N/A
  • Revenue Next Year
  • CALC N/A
  • ORIS N/A
  • P/E Ratio
  • CALC N/A
  • ORIS $3.60
  • Revenue Growth
  • CALC N/A
  • ORIS N/A
  • 52 Week Low
  • CALC $1.42
  • ORIS $0.50
  • 52 Week High
  • CALC $5.97
  • ORIS $56.01
  • Technical
  • Relative Strength Index (RSI)
  • CALC 48.14
  • ORIS N/A
  • Support Level
  • CALC $1.59
  • ORIS N/A
  • Resistance Level
  • CALC $1.69
  • ORIS N/A
  • Average True Range (ATR)
  • CALC 0.15
  • ORIS 0.00
  • MACD
  • CALC 0.01
  • ORIS 0.00
  • Stochastic Oscillator
  • CALC 46.51
  • ORIS 0.00

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

About ORIS Oriental Rise Holdings Limited Ordinary Shares

Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).

Share on Social Networks: